What to test in Parkinson disease prevention trials? Repurposed, low-risk, and gene-targeted drugs

GF Crotty, MA Schwarzschild - Neurology, 2022 - AAN Enterprises
Despite the sound epidemiologic and basic science rationales underpinning numerous
“disease modification” trials in manifest Parkinson disease (PD), none has convincingly …

What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.

GF Crotty, MA Schwarzschild - Neurology, 2022 - europepmc.org
Despite the sound epidemiologic and basic science rationales underpinning numerous
“disease modification” trials in manifest Parkinson disease (PD), none has convincingly …

[HTML][HTML] What to Test in Parkinson Disease Prevention Trials?: Repurposed, Low-Risk, and Gene-Targeted Drugs

GF Crotty, MA Schwarzschild - Neurology, 2022 - ncbi.nlm.nih.gov
Despite the sound epidemiologic and basic science rationales underpinning numerous
“disease modification” trials in manifest Parkinson disease (PD), none has convincingly …

[PDF][PDF] What to Test in Parkinson Disease Prevention Trials?

LR Repurposed - Neurology, 2022 - pdfs.semanticscholar.org
Despite the sound epidemiologic and basic science rationales underpinning numerous
“disease modification” trials in manifest Parkinson disease (PD), none has convincingly …

What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs

GF Crotty, MA Schwarzschild - Neurology, 2022 - pubmed.ncbi.nlm.nih.gov
Despite the sound epidemiologic and basic science rationales underpinning numerous"
disease modification" trials in manifest Parkinson disease (PD), none has convincingly …

What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.

GF Crotty, MA Schwarzschild - Neurology, 2022 - europepmc.org
Despite the sound epidemiologic and basic science rationales underpinning numerous"
disease modification" trials in manifest Parkinson disease (PD), none has convincingly …